ArticleClinical rheumatology2026
Assessing rheumatoid arthritis prevalence from 1990 to 2040: viewing global inequities through the lens of sociodemographic development.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesRheumatoid arthritis (RA) imposes a substantial global health burden, contributing significantly to chronic disability and escalating healthcare costs. Accurate, long-term prevalence forecasts are essential to inform strategic planning for rheumatology services and health resource allocation.
methodsHence, we developed and calibrated a sex-specific illness-death model (IDM) at global, regional, and national scales using GBD data (1990-2021). To uncover underlying epidemiological patterns, we augmented our projections with a frontier analysis that evaluates the efficiency of RA burden relative to sociodemographic index (SDI).
resultsWe project the global age-standardized prevalence rate (ASPR) will rise by 6.3% to 222.06 per 100,000 (95% CI, 220.49-223.6) by 2040. While females bear a higher absolute prevalence, the growth rate is projected to be faster in males (8.75% vs. 5.67%). Significant disparities exist at regional and national levels: Andean Latin America and Peru are anticipated to have the highest ASPRs, while Oceania and Indonesia are projected to have the lowest. An increasing trend is projected globally, across 18 GBD regions, and in 167 nations. Critically, frontier analysis reveals that higher sociodemographic development frequently coincides with a larger "RA efficiency gap," indicating economic progress alone is insufficient for disease control.
conclusionTherefore, mitigating the projected rise in RA requires strategies that move beyond relying on general economic advancement. Future health policies must actively integrate targeted prevention of modifiable lifestyle risks and bridge healthcare access gaps to effectively curb the coming global burden. Key Points • Projects a 6.3% global increase in RA prevalence by 2040, with faster growth in males. • Identifies an "RA efficiency gap" where higher development correlates with higher burden. • Forecasts severe geographic disparities, with Andean Latin America having the highest burden. • Concludes that targeted prevention, not just economic progress, is needed to curb future burden.
Indexed as
Identifiers
42115579What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.